Angiotensin-Converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats

American Journal of Hypertension

Volumn 17, Issue 2, 2004, Pages 172-180

  Toblli, Jorge E ^a   Cao, Gabriel ^a   DeRosa, Graciela ^b   Di Gennaro, Federico ^a   Forcada, Pedro ^a  

^a HOSPITAL ALEMÁN   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Angiogenesis; Angiotensin converting enzyme inhibitors; Diabetes; Myocardium; Obesity

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; NITRIC OXIDE SYNTHASE; PERINDOPRIL; RECA PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME INHIBITION; EXPERIMENTAL MODEL; FEEDING; GLUCOSE BLOOD LEVEL; HEART MUSCLE CELL; HEART PROTECTION; HEART WEIGHT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPECIES COMPARISON; TISSUE SECTION;

EID: 1642452756     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2003.10.006     Document Type: Article

References (54)

1. Luo F., Wariaro D., Lundberg G., Blegen H., Wahlberg E. Vascular growth factor expression in a rat model of severe limb ischemia. J Surg Res. 108:2002;258-267.
2. Lind L., Lithell H. Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia. Am Heart J. 125:1993;1494-1497.
3. Larouche I., Schiffrin E.L. Cardiac microvasculature in DOCA-salt hypertensive rats effect of endothelin ET(A) receptor antagonism . Hypertension. 34:1999;795-801.
4. Warley A., Powell J.M., Skepper J.N. Capillary surface area is reduced and tissue thickness from capillaries to myocytes is increased in the left ventricle of streptozotocin-diabetic rats. Diabetologia. 38:1995;413-421.
5. Noon J.P., Walker B.R., Webb D.J., Shore A.C., Holton D.W., Edwards H.V., et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest. 99:1997;1873-1879.
6. Gohlke P., Linz W., Scholkens B., Van Even P., Martorana P., Unger T. Vascular and cardiac protection by ramipril in spontaneously hypertensive rats prevention versus regression study . Br J Clin Pract Suppl. 84:1996;1-10.
7. Sugawara T., Fujii S., Akm Zaman T., Goto D., Kaneko T., Furumoto T., Togashi H., Yoshioka M., Koyama T., Kitabatake A. Coronary capillary remodeling in non-insulin-dependent diabetic rats amelioration by inhibition of angiotensin converting enzyme and its potential clinical implications . Hypertens Res. 24:2001;75-81.
8. Cameron N.E., Cotter M.A., Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia. 35:1992;12-18.
9. Gohlke P., Kuwer I., Schnell A., Amann K., Mall G., Unger T. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension. 29:1997;478-482.
10. Jeanrenaud B. Neuroendocrine and metabolic basis of type II diabetes as studied in animal models. Diabetes Metab Rev. 4:1988;603-614.
11. Shimaya A., Noshiro O., Hirayama R., Yoneta T., Niigata K., Shikama H. Insulin sensitizer YM268 ameliorates insulin resistance by normalizing the decreased content of GLUT4 in adipose tissue of obese Zucker rats. Eur J Endocrinol. 137:1997;693-700.
12. Fujiwara K., Hayashi K., Matsuda H., Kubota E., Honda M., Ozawa Y., Saruta T. Altered pressure-natriuresis in obese Zucker rats. Hypertension. 33:1999;1470-1475.
13. Kurtz T.W., Morris R.C., Pershadsingh H.A. The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension. 13:1989;896-901.
14. Turner N.C., Gudgeon C., Toseland N. Effects of genetic hyperinsulinaemia on vascular reactivity, blood pressure, and renal structure in the Zucker rat. J Cardiovasc Pharmacol. 26:1995;714-720.
15. Hussain T., Beheray S.A., Lokhandwala M.F. Defective dopamine receptor function in proximal tubules of obese zucker rats. Hypertension. 34:1999;1091-1096.
16. Toblli J.E., DeRosa G., Rivas C., Cao G., Piorno P., Pagano P., Forcada P. Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats. J Hypertens. 1:2003;611-620.
17. Takeshita S., Tomiyama H., Yokoyama N., Kawamura Y., Furukawa T., Ishigai Y., Shibano T., Isshiki T., Sato T. Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats. Cardiovasc Res. 52:2001;314-320.
18. Hsu S.M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) immunoperoxidase techniques a comparison between ABC an unlabeled antibody (PAP) procedures . J Histochem Cytochem. 29:1981;577-580.
19. Takeshita S., Tomiyama H., Yokoyama N., Kawamura Y., Furukawa T., Ishigai Y., Shibano T., Isshiki T., Sato T. Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats. Cardiovasc Res. 52:2001;314-320.
20. Silvestre J.S., Kamsu-Kom N., Clergue M., Duriez M., Levy B.I. Very-low-dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs. J Pharmacol Exp Ther. 303:2002;1038-1043.
21. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest. 106:2000;453-458.
22. Huisamen B., van Zyl M., Keyser A., Lochner A. The effects of insulin and beta-adrenergic stimulation on glucose transport, glut 4 and PKB activation in the myocardium of lean and obese non-insulin dependent diabetes mellitus rats. Mol Cell Biochem. 223:2001;15-25.
23. Kolter T., Uphues I., Eckel J. Molecular analysis of insulin resistance in isolated ventricular cardiomyocytes of obese Zucker rats. Am J Physiol. 273:1997;E59-E67.
24. Rett K., Wicklmayr M., Dietze G.J., Haring H.U. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes. 45:(Suppl 1):1996;S66-S69.
25. Jiang Z.Y., Lin Y.W., Clemont A., Feener E.P., Hein K.D., Igarashi M., Yamauchi T., White M.F., King G.L. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 104:1999;447-457.
26. Zhou Y.T., Grayburn P., Karim A., Shimabukuro M., Higa M., Baetens D., Orci L., Unger R.H. Lipotoxic heart disease in obese rats implications for human obesity . Proc Natl Acad Sci U S A. 97:2000;1784-1789.
27. Asakawa M., Takano H., Nagai T., Uozumi H., Hasegawa H., Kubota N., Saito T., Masuda Y., Kadowaki T., Komuro I. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 105:2002;1240-1246.
28. Duarte J., Martinez A., Bermejo A., Vera B., Gamez M.J., Cabo P., Zarzuelo A. Cardiovascular effects of captopril and enalapril in obese Zucker rats. Eur J Pharmacol. 365:1999;225-232.
29. Uehara M., Kishikawa H., Isami S., Kisanuki K., Ohkubo Y., Miyamura N., Miyata T., Yano T., Shichiri M. Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulfhydryl group bradykinin may improve insulin resistance in dogs and humans . Diabetologia. 37:1994;300-307.
30. Henriksen E.J., Jacob S. Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism. 44:1995;267-272.
31. Vuirinen-Markkola H., Yki-Järvinen H. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism. 44:1995;85-89.
32. Fogari R., Zoppi A., Lazzari P., Preti P., Mugellini A., Corradi L., Lusardi P. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol. 32:1998;616-620.
33. Henriksen E.J., Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol. 196:2003;171-179.
34. Folli F., Kahn C.R., Hansen H., Bouchie J.L., Feener E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest. 100:1997;2158-2169.
35. Higashiura K., Ura N., Takada T., Li Y., Torii T., Togashi N., Takada M., Takizawa H., Shimamoto K. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens. 13:2000;290-297.
36. Shiuchi T., Cui T.X., Wu L., Nakagami H., Takeda-Matsubara Y., Iwai M., Horiuchi M. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension. 40:2002;329-334.
37. Walker A.B., Dores J., Buckingham R.E., Savage M.W., Williams G. Impaired insulin-induced attenuation of noradrenaline-mediated vasoconstriction in insulin-resistant obese Zucker rats. Clin Sci. 93:1997;235-241.
38. Chou E., Suzuma I., Way K.J., Opland D., Clermont A.C., Naruse K., Suzuma K., Bowling N.L., Vlahos C.J., Aiello L.P., King G.L. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states a possible explanation for impaired collateral formation in cardiac tissue . Circulation. 105:2002;373-379.
39. Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldi S, Van Obberghen E: Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem 2000;275:21695-21702.
40. Jesmin S., Hattori Y., Sakuma I., Mowa C.N., Kitabatake A. Role of ANG II in coronary capillary angiogenesis at the insulin-resistant stage of a NIDDM rat model. Am J Physiol Heart Circ Physiol. 283:2002;H1387-H1397.
41. Tamarat R., Silvestre J.S., Durie M., Levy B.I. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest. 82:2002;747-756.
42. Tamarat R., Silvestre J.S., Kubis N., Benessiano J., Duriez M., deGasparo M., Henrion D., Levy B.I. Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hindlimb. Hypertension. 39:2002;830-835.
43. Sasaki K., Murohara T., Ikeda H., Sugaya T., Shimada T., Shintani S., Imaizumi T. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest. 109:2002;603-611.
44. Silvestre J.S., Tamarat R., Senbonmatsu T., Icchiki T., Ebrahimian T., Iglarz M., Besnard S., Duriez M., Inagami T., Levy B.I. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res. 90:2002;1072-1079.
45. Fabre J.E., Rivard A., Magner M., Silver M., Isner J.M. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation. 99:1999;3043-3049.
46. Balcells E., Meng Q.C., Johnson W.H. Jr, Oparil S., Dell'Italia L.J. Angiotensin II formation from ACE and chymase in human and animal hearts methods and species considerations . Am J Physiol. 273:1997;H1769-H1774.
47. Akasu M., Urata H., Kinoshita A., Sasaguri M., Ideishi M., Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension. 32:1998;514-520.
48. Ziche M., Morbidelli L., Masini E., Amerini S., Granger H.J., Maggi C.A., Geppetti P., Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest. 94:1994;2036-2044.
49. Leibovich S.J., Polverini P.J., Fong T.W., Harlow L.A., Koch A.E. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci U S A. 91:1994;4190-4194.
50. Dimmeler S., Hermann C., Galle J., Zeiher A.M. Upregulation of superoxide dismutase and nitric oxide synthase mediates the apoptosis- suppressive effects of shear stress on endothelial cells. Arterioscler Thromb Vasc Biol. 19:1999;656-664.
51. Dulak J., Jozkowicz A., Dembinska-Kiec A., Guevara I., Zdzienicka A., Zmudzinska-Grochot D., Florek I., Wojtowicz A., Szuba A., Cooke J.P. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 20:2000;659-666.
52. Zhang X., Xie Y.W., Nasjletti A., Xu X., Wolin M.S., Hintze T.H. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation. 95:1997;176-182.
53. Zhuo J.L., Mendelsohn F.A., Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension. 39:2002;634-638.
54. Silvestre J.S., Bergaya S., Tamarat R., Duriez M., Boulanger C.M., Levy B.I. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res. 89:2001;678-683.